Tag
AbICL proposes an in-context learning framework for antigen-specific antibody affinity ranking, combining a pretrained structural encoder with a context ranking head to leverage labeled demonstrations for test-time adaptation without gradient updates.
British startup Mass Balance launched a self-contained autonomous laboratory into orbit to study disease-causing disordered proteins under microgravity, aiming to generate data to train AI models for drug discovery. The test mission will validate the system's ability to run chemical experiments in space.
A device called the Eye-in-a-Care-Box (ECaBox) can revive eyes from dead donors by perfusing them with oxygen-rich fluid, preserving retinal function and potentially enabling whole-eye transplants.
A subscriber-only roundtable discussion hosted by MIT Technology Review explores the frontier of longevity research, focusing on cellular reprogramming as a potential treatment to reverse aging.
Arc Institute announces Germinal, a generative AI system for de novo antibody design published in Nature Biotechnology. It designs epitope-targeted antibodies with nanomolar affinity testing only tens of designs per target, making custom antibody design more accessible.
The article discusses how patents on plant varieties in the US stifle competition and innovation in the seed industry, allowing a few corporations to dominate and divert taxpayer subsidies to profits.
FDA advisors voted unanimously to approve Moderna's seasonal mRNA flu vaccine, mRNA-1010, after initial rejection by a Trump appointee. The vaccine showed 27% better efficacy than standard flu shot and stronger immune response than high-dose vaccine in older adults.
CRISPR technology has been developed to selectively target and destroy cancer cells, including those previously considered undruggable.
A biotech company has dosed its first volunteer in a clinical trial for an experimental glaucoma treatment that uses cellular reprogramming to reverse age-related damage, part of a broader trend toward rejuvenation therapies.
Researchers have genetically engineered hookworms to secrete human therapeutic antibodies directly into the host's bloodstream, demonstrating a potential single-dose, long-term drug delivery platform using parasitic nematodes as biofactories.
Debug is a project using sterile male mosquitoes with Wolbachia bacteria to reduce populations of disease-carrying mosquitoes like Aedes aegypti.
Scientists have discovered the missing genes and enzyme that tobacco plants use to synthesize nicotine, solving a 200-year-old mystery. The finding could enable safer biotech production of medicines and vaccines using tobacco plants without nicotine contamination.
The inaugural Enhanced Games, where athletes are encouraged to use performance-enhancing drugs, reflects societal trends toward human enhancement and longevity in 2026. The event offers substantial prizes and raises questions about safety and ethics.
A de-extinction company has successfully hatched live chicks from artificial eggshells, a significant milestone in biotechnology that could advance de-extinction efforts.
Colossal Biosciences successfully hatched 26 chickens using synthetic eggshells, a key step toward de-extinction of birds like the dodo and moa.
Colossal Biosciences announced a 3D-printed artificial eggshell to grow chicken embryos, aiming to revive extinct birds like the dodo and moa, though experts note prior similar work.
MIT researcher Lauren Ramlan published a paper demonstrating that the classic game Doom can be played on a display made from E. coli cells, though at an extremely slow frame rate that would take centuries to complete a single playthrough.
The article introduces Illumina, the global gene sequencing giant, accompanying Trump on his visit to China, attempting to lift China's import ban on its gene sequencers. It also points out that BGI (Huada Gene) had already laid out its independent technology route by acquiring Complete Genomics, changing the market landscape.